Fera Initiates Shipping Of Bacitracin Ophthalmic Ointment, USP

The company expects to have available the 3.5g tube size in cartons of 24, Hospital –Pak, as well as the single 3.5g tube package size over the next few weeks.

Reportedly, in July 2009, Fera has acquired all rights and title to seven ophthalmic ointments, including Bacitracin. Product supply has been an issue since then, as the previous owner had discontinued manufacture of Bacitracin and only a limited quantity was made available during the transition to Fera.

Frank DellaFera, president of Fera, said: “Fera has made the completion of Erythromycin 1g manufacturing transfer a priority, responding to the market shortage. We are genuinely pleased to be able to help hospitals provide the standard of care they demand.”

Erythromycin ophthalmic ointment USP belongs to the macrolide group of antibiotics. The sterile ophthalmic ointment flows freely over the conjunctiva. Erythromycin base, as crystals or powder, is slightly soluble in water, moderately soluble in ether, and readily soluble in alcohol or chloroform. Erythromycin is an antibiotic produced from a strain of streptomyces erythraeus.